title: Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group.
abstract: Continuous infusion with coagulation factor concentrates has only been widely adopted during the last decade and with recombinant activated factor VII (rFVIIa) only during the last 2 years. Still the accumulated number of days on continuous infusion with this product amounts by now to more than one year, 35 patients and 26 surgical procedures. The experience is reviewed here and compared with data from the conventional bolus dose regimen.
authors.affiliation: Coagulation Unit, Karolinska Hospital, Stockholm, Sweden. ssc@divmed.ks.se
authors.forename: S
authors.initials: S
authors.lastname: Schulman
mesh_terms: D015942:Factor VIIa / Q000008:administration & dosage* / Q000009:adverse effects; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors
chemical_list: D011994:Recombinant Proteins; D015942:Factor VIIa